Skip Navigation
Department of Health and Human Services
Slide Tray
0 slides

Return to Slide Library


Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 22 of 45

Summary of Results: Head-to-Head Comparisons of Biologic DMARDs

Head-to-head comparisons of biologic DMARDs were evaluated for the effectiveness review. Patient populations in the included studies were patients with active RA for longer than 3 years whose disease not did respond or inadequately responded to DMARDs but had not previously treated with an anti–TNF-α DMARD. This table presents a summary of the results of those studies, organized according to the interventions compared in each study. Disease activity and symptom response, functional status, and quality-of-life outcomes were reported. Radiographic evidence of progression was not reported in the studies. The evidence is limited for all comparisons; thus, the strength of evidence is low or insufficient.

ACR70 = American College of Rheumatology 70-percent improvement criteria; ACR20 = American College of Rheumatology 20-percent improvement criteria; DAS = Disease Activity Score; DMARD = disease-modifying anti-rheumatic drug; MCID = minimum clinically important difference; NSD = no statistically significant difference; RA = rheumatoid arthritis; SOE = strength of evidence; TNF-α = tumor necrosis factor-alpha